logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
MiNK Therapeutics Announces Complete Remission in Metastatic Testicular Cancer Using iNKT Cell TherapyClinical Trial Updates

MiNK Therapeutics Announces Complete Remission in Metastatic Testicular Cancer Using iNKT Cell Therapy

MiNK Therapeutics announced the publication of a case report in *Oncogene* showing complete and durable remission in a patient with metastatic, treatm...

Danish Study Finds No Link Between Aluminum in Vaccines and 50 Health ConditionsClinical Trial Updates

Danish Study Finds No Link Between Aluminum in Vaccines and 50 Health Conditions

A large-scale Danish register-based study involving over 1 million children found no association between aluminum in childhood vaccines and 50 health ...

MiraDx's MicroRNA-based Platform Predicts Cancer Treatment OutcomesClinical Trial Updates

MiraDx's MicroRNA-based Platform Predicts Cancer Treatment Outcomes

MiraDx announced two studies to be presented at ASCO 2025, showcasing their mirSNP platform's ability to predict treatment-related toxicity and respon...

Avant Technologies and Ainnova Complete Pivotal FDA Meeting for Vision AI Diabetic Retinopathy PlatformClinical Trial Updates

Avant Technologies and Ainnova Complete Pivotal FDA Meeting for Vision AI Diabetic Retinopathy Platform

Avant Technologies and its JV partner, Ainnova, announced the completion of a pre-submission meeting with the U.S. FDA regarding Ainnova's Vision AI p...

Moderna Announces Positive Phase 3 Results for Seasonal Influenza VaccineClinical Trial Updates

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna announced positive Phase 3 results for its seasonal influenza vaccine candidate, mRNA-1010. The study demonstrated a 26.6% higher relative va...

DecisionDx-Melanoma Test Outperforms Existing Methods in Identifying Low-Risk Melanoma PatientsClinical Trial Updates

DecisionDx-Melanoma Test Outperforms Existing Methods in Identifying Low-Risk Melanoma Patients

A new study published in Cancer Diagnosis & Prognosis shows that Castle Biosciences' DecisionDx-Melanoma test surpasses both American Joint Committee ...

MolecuLight Imaging Improves Deep Sternal Wound Infection Outcomes and Reduces Costs in Taiwan StudyClinical Trial Updates

MolecuLight Imaging Improves Deep Sternal Wound Infection Outcomes and Reduces Costs in Taiwan Study

A clinical study published in the Journal of Wound Care demonstrates that MolecuLight's i:X® device significantly improves outcomes for deep sternal w...

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative ColitisClinical Trial Updates

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax announced positive topline results from its Phase 3 ABTECT-1 and ABTECT-2 trials evaluating obefazimod, a first-in-class oral miR-124 enhancer,...

Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan DiseaseClinical Trial Updates

Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease

Myrtelle Inc. announced encouraging interim results from its Phase 1/2 clinical trial of rAAV-Olig001-ASPA (MYR-101), an investigational gene therapy ...

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025Clinical Trial Updates

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025

Disc Medicine will present data from its Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anem...

Nadunolimab Plus Pembrolizumab Shows Potential in Solid TumorsClinical Trial Updates

Nadunolimab Plus Pembrolizumab Shows Potential in Solid Tumors

Cantargia announced the publication of clinical trial results in Investigational New Drugs, showing the potential of nadunolimab combined with pembrol...

Avidicure to Present Preclinical Data on TROP2-Targeting Antibody at ASCO 2025Clinical Trial Updates

Avidicure to Present Preclinical Data on TROP2-Targeting Antibody at ASCO 2025

Avidicure announced it will present preclinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights AVC...

NervGen Announces Leadership Transition and Positive Chronic Spinal Cord Injury Trial Results for NVG-291Clinical Trial Updates

NervGen Announces Leadership Transition and Positive Chronic Spinal Cord Injury Trial Results for NVG-291

NervGen Pharma Corp. announced a leadership transition with Dr. Adam Rogers appointed as Interim CEO, following the positive topline results from the ...

EMD Serono Presents Oncology Data at ASCO 2025Clinical Trial Updates

EMD Serono Presents Oncology Data at ASCO 2025

EMD Serono announced the presentation of new oncology data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key highlights in...

Neurocrine Biosciences Initiates Phase 3 Trial for NBI-1117568 in SchizophreniaClinical Trial Updates

Neurocrine Biosciences Initiates Phase 3 Trial for NBI-1117568 in Schizophrenia

Neurocrine Biosciences has initiated a Phase 3 registrational program for NBI-1117568, an oral muscarinic M4 selective receptor agonist, as a potentia...

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine TumorsClinical Trial Updates

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors

AlphaMedix phase 2 study (ALPHAMEDIX-02) evaluating AlphaMedix (212Pb-DOTAMTATE) in patients with advanced gastroenteropancreatic neuroendocrine tumor...

Neuvivo Secures FDA Alignment for NP001 ALS Treatment and Appoints Dr. John Curnutte to BoardClinical Trial Updates

Neuvivo Secures FDA Alignment for NP001 ALS Treatment and Appoints Dr. John Curnutte to Board

Neuvivo, Inc., a late-stage biopharmaceutical company, announced it has reached an agreement with the FDA on the regulatory pathway for NP001, an immu...

Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor ConferencesClinical Trial Updates

Editas Medicine Announces EDIT-401 Oral Presentation at ESGCT Congress and Participation in Investor Conferences

Editas Medicine announced an oral presentation on EDIT-401, a CRISPR gene editing medicine for lowering LDL-cholesterol by upregulating LDLR, at the E...

Novo Nordisk Advances Amycretin for Weight Management to Phase 3Clinical Trial Updates

Novo Nordisk Advances Amycretin for Weight Management to Phase 3

Novo Nordisk announced its advancement of both subcutaneous and oral amycretin into phase 3 clinical development for weight management. This decision ...

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension TrialClinical Trial Updates

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial

Positive results from the BaxHTN Phase III trial demonstrated that baxdrostat, a highly selective aldosterone synthase inhibitor, significantly reduce...

Novo Nordisk to Present New Data on Semaglutide, CagriSema, and Amycretin at ADA 2025Clinical Trial Updates

Novo Nordisk to Present New Data on Semaglutide, CagriSema, and Amycretin at ADA 2025

Novo Nordisk announced it will present new data at the American Diabetes Association (ADA) 85th Scientific Sessions in June 2025. This includes Phase...

Endogenex Presents Positive 48-Week REGENT-1 Clinical Trial Results for Type 2 Diabetes TreatmentClinical Trial Updates

Endogenex Presents Positive 48-Week REGENT-1 Clinical Trial Results for Type 2 Diabetes Treatment

Endogenex announced positive 48-week results from its REGENT-1 clinical study at Digestive Disease Week 2025. The study evaluated the safety and effic...

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at AACR-NCI-EORTC ConferenceClinical Trial Updates

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at AACR-NCI-EORTC Conference

Nuvectis Pharma, Inc. announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and ...

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic ShockClinical Trial Updates

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic Shock

4TEEN4 Pharmaceuticals announced the publication of data in the European Journal of Heart Failure demonstrating the efficacy and safety of procizumab,...

OKYO Pharma's Urcosimod Shows Promising Phase 2 Results for Neuropathic Corneal PainClinical Trial Updates

OKYO Pharma's Urcosimod Shows Promising Phase 2 Results for Neuropathic Corneal Pain

OKYO Pharma announced positive top-line data from its Phase 2 trial of urcosimod for treating neuropathic corneal pain (NCP). The 18-patient trial sh...

Envoy Medical's Pivotal Trial for Acclaim® Cochlear Implant Shows Positive One-Month Follow-Up ResultsClinical Trial Updates

Envoy Medical's Pivotal Trial for Acclaim® Cochlear Implant Shows Positive One-Month Follow-Up Results

Envoy Medical announced positive one-month follow-up results from the first stage of its pivotal clinical trial for the fully implanted Acclaim® Cochl...

ONWARD Medical Achieves Fifth Successful Brain-Computer Interface ImplantClinical Trial Updates

ONWARD Medical Achieves Fifth Successful Brain-Computer Interface Implant

ONWARD Medical announced the successful implantation of its investigational ARC-BCI® Therapy in two additional individuals with spinal cord injury, br...

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck CancerClinical Trial Updates

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics announced updated interim data from a Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for first-lin...

OS Therapies Announces Positive Phase 2b Data for OST-HER2 in OsteosarcomaClinical Trial Updates

OS Therapies Announces Positive Phase 2b Data for OST-HER2 in Osteosarcoma

OS Therapies announced positive one-year event-free survival (EFS), overall survival, and safety data from its Phase 2b trial of OST-HER2 in patients ...

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal CancerClinical Trial Updates

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer

Exelixis announced detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in...

OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical DevelopmentClinical Trial Updates

OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical Development

OS Therapies Inc. announces its participation in the BioFuture 2025 conference, where it will present an overview of the company with a focus on the c...

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101Clinical Trial Updates

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101

Alto Neuroscience announced positive results from an independent, prospective replication study validating theta-band inter-trial coherence (ITC) as a...

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet AMDClinical Trial Updates

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet AMD

EyePoint Pharmaceuticals announced the completion of enrollment for its Phase 3 LUCIA trial evaluating DURAVYU™ for wet age-related macular degenerati...

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain TherapyClinical Trial Updates

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain Therapy

4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for chronic pain. The trial demon...

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid LeukemiaClinical Trial Updates

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

AB Science SA announced initial Phase 1 data for the combination of AB8939 with venetoclax for treating refractory or relapsed acute myeloid leukemia ...

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in VitiligoClinical Trial Updates

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

AbbVie announced positive topline results from two replicate Phase 3 studies evaluating upadacitinib (RINVOQ®) in adult and adolescent patients with n...

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised PatientsClinical Trial Updates

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

Aicuris Anti-infective Cures AG announced positive results from its Phase 3 trial (PRIOH-1) of pritelivir for treating refractory Herpes Simplex Virus...

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 PresentationClinical Trial Updates

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 Presentation

Ascentage Pharma announced positive clinical data for lisaftoclax, a Bcl-2 inhibitor, and alrizomadlin, an MDM2-p53 inhibitor. Data from a Phase 1b/2...

Candel Therapeutics to Present CAN-2409 Data at SITC 2025Clinical Trial Updates

Candel Therapeutics to Present CAN-2409 Data at SITC 2025

Candel Therapeutics will present data from its enLIGHTEN™ Discovery Platform and CAN-2409 program in non-small cell lung cancer (NSCLC) at the SITC 20...

ITM to Present COMPETE Trial Data at SNMMI 2025 Annual MeetingClinical Trial Updates

ITM to Present COMPETE Trial Data at SNMMI 2025 Annual Meeting

ITM Isotope Technologies Munich SE announced that it will present further analysis from its completed Phase 3 COMPETE trial at the SNMMI 2025 annual m...

← PrevPage 5 of 8Next →

Get a Demo of the Enterprise AI & Knowledge Platform

Private by design. Speaks your language. Proven at scale

Book a Demo